BACKGROUND: Secukinumab is a fully human anti-interleukin-17A monoclonal 
antibody.
OBJECTIVE: Determine the efficacy, safety and usability of secukinumab 
administered via autoinjector/pen.
METHODS: This phase III trial randomized subjects with moderate to severe plaque 
psoriasis to secukinumab 300 mg, 150 mg or placebo self-injection once weekly to 
Week 4, then every 4 weeks. Co-primary end points at Week 12 were ≥75% 
improvement in Psoriasis Area and Severity Index (PASI 75) and clear/almost 
clear skin by investigator's global assessment 2011 modified version (IGA mod 
2011 0/1). Secondary end points included autoinjector usability, assessed by 
successful, hazard-free self-injection and subject-reported acceptability on 
Self-Injection Assessment Questionnaire.
RESULTS: Week 12 PASI 75 and IGA mod 2011 0/1 responses were superior with 
secukinumab 300 mg (86.7% and 73.3%, respectively) and 150 mg (71.7% and 53.3%, 
respectively) vs. placebo (3.3% and 0%, respectively) (P < 0.0001 for all). All 
subjects successfully self-administered treatment at Week 1, without critical 
use-related hazards. Subject acceptability of autoinjector was high throughout 
12 weeks. Adverse events were higher with secukinumab (300 mg, 70.0%; 150 mg, 
63.9%) vs. placebo (54.1%), with differences largely driven by mild/moderate 
nasopharyngitis.
CONCLUSION: Secukinumab delivered by autoinjector/pen is efficacious, 
well-tolerated and associated with high usability in moderate to severe plaque 
psoriasis.